- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Part D plans cover fewer anticonvulsants
Fewer anticonvulsant medications were on the inexpensive Part D formulary tiers than in the commercial plans
Despite being considered a protected class of drugs, anticonvulsant medications for the treatment of epileptic seizures had lower levels of coverage for Medicare prescription drug plans (PDPs) than commercial health plans.
A recent Avalere Health study, supported by UCB, Inc., also showed that fewer anticonvulsant medications were on the inexpensive formulary tiers than in the commercial plans.
The pricing and limited coverage could have an adverse impact on Medicare patients’ access to the class of medications and has the potential to create negative health outcomes. Those negative outcomes are one of the reasons why the Centers for Medicare and Medicaid Services created the protected-class policy.
“Benefit design should be employed to keep costs low by incentivizing the patient to do the right thing,” says Dan Mendelson, CEO of Avalere Health. “High cost-sharing for needed medications-and in particular medications that can control illness-can introduce perversities by making it harder for patients to comply with best practice.”
The protected-class policy requires PDPs to cover all medicines within a class-with some exceptions such as extended-release formulations-but does not otherwise define “protection.”
The Avalere study showed that commercial health plans offered more coverage for anticonvulsants on formularies than PDPs, particularly with brand-name and extended-release medications.
“The core of this debate is around what constitutes insurance,” Mendelson says. “Consumers will increasingly expect that when they get really sick, insurance will cover the cost. High cost-sharing for products and services that are needed by seriously ill patients are incompatible with that vision.”
Utilization management technique usage was roughly equivalent between PDPs and commercial plans.
Specialty tier medicines prove to have the most substantial differences in cost-sharing between coinsurance and fixed copayment. According to a Government Accountability Office report, the median negotiated price for a specialty drug on the highest tier in 2007 was $1,100. Patients in commercial plans would pay on average $79 for that drug. Medicare patients in PDPs would pay roughly 30% of the drug’s $1,100 each month, around $330.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More
